Literature DB >> 6873135

Amiodarone and pulmonary fibrosis.

J Morera, R Vidal, F Morell, J Ruiz, L Bernadó, J R Laporte.   

Abstract

Of 25 cases of idiopathic pulmonary fibrosis, confirmed by open chest lung biopsy between January 1979 and July 1981, 5 patients had been taking amiodarone in doses less than 600 mg daily for 1 to 6 years. No lung disease had been observed in any patient before the administration of amiodarone, and other drugs, factors and diseases thought to play a role in the causation of pulmonary fibrosis were ruled out. Two patients died of respiratory insufficiency, and only 1 does not now suffer from serious sequelae. Review of a further 5 cases reported in the literature and the present data suggest a causal link between administration of amiodarone and pulmonary fibrosis, and tend to indicate a hypersensitivity mechanism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6873135     DOI: 10.1007/bf00542206

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  A peculiar cutaneous pigmentation from cordarone.

Authors:  A K Vos; A G van Ramshorst; J C Grosfeld; J P Goossens
Journal:  Dermatologica       Date:  1972

2.  Alveolitis after treatment with amiodarone.

Authors:  S A Riley; S E Williams; N J Cooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-16

3.  Pulmonary infiltration and bone marrow depression complicating treatment with amiodarone.

Authors:  A J Wright; R G Brackenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-01

Review 4.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

5.  Possible association of pneumonitis with amiodarone therapy.

Authors:  H H Rotmensch; M Liron; M Tupilski; S Laniado
Journal:  Am Heart J       Date:  1980-09       Impact factor: 4.749

6.  Effects of amiodarone on thyroid function in patients with ischaemic heart disease.

Authors:  D A Pritchard; B N Singh; P J Hurley
Journal:  Br Heart J       Date:  1975-08

7.  Clinical efficacy of amiodarone as an antiarrhythmic agent.

Authors:  M B Rosenbaum; P A Chiale; M S Halpern; G J Nau; J Przybylski; R J Levi; J O Lázzari; M V Elizari
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778

8.  Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug.

Authors:  S M Sobol; L Rakita
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

9.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

  9 in total
  2 in total

1.  Amiodarone pneumonitis: three further cases with a review of published reports.

Authors:  J I Darmanata; N van Zandwijk; D R Düren; E A van Royen; W J Mooi; T A Plomp; H M Jansen; D Durrer
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

Review 2.  Amiodarone pulmonary toxicity.

Authors:  N Wolkove; M Baltzan
Journal:  Can Respir J       Date:  2009 Mar-Apr       Impact factor: 2.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.